Summary
- A study analyzed 205 dogs with B-cell lymphoma, with the most common subtype being diffuse large B-cell lymphoma (DLBCL).
- Treatment varied based on the subtype, with most dogs receiving chemo-immunotherapy.
- Dogs treated with chemo-immunotherapy had longer time to progression and lymphoma-specific survival compared to those treated with chemotherapy alone.
- Genetic analysis of canine lymphomas identified common mutations in genes such as TRAF3, POT1, and FBXW7.
- Mutations in genes like TP53 and SETD2 were associated with shorter time to progression and overall survival in both B-cell and T-cell lymphomas.
A study on dogs with lymphoma revealed important findings about the genetic landscape of the disease. The research looked at different types of lymphoma in dogs, including B-cell and T-cell lymphomas. In B-cell lymphoma, mutations in genes like TRAF3, POT1, FBXW7, MYC, DDX3X, and SETD2 were frequently observed. These mutations were linked to shorter time to disease progression and overall survival in both aggressive and indolent forms of B-cell lymphoma. Specifically, mutations in TP53 and SETD2 were found to impact the prognosis of dogs with B-cell lymphoma.
In T-cell lymphoma, mutations in genes like SATB1, FBXW7, FAT4, and ARPC1A were identified in aggressive forms of the disease. These mutations were associated with different outcomes in terms of disease progression and survival. On the other hand, indolent T-cell lymphomas showed fewer genetic alterations, with SETD2 being the most commonly mutated gene.
Overall, the study highlighted the significance of specific gene mutations in predicting outcomes for dogs with lymphoma. Understanding these genetic factors can help veterinarians tailor treatment plans and improve the prognosis for furry friends battling this type of cancer.
Source link
Oncology, Pathology&LabMedicine